CANCELLED - SECTION 8
section 8
on 28 May 2024
Last Applicant/ Owned by
Meditrina, Babraham Research Campus
Cambridge
GB
CB223AT
Serial Number
87052324 filed on 27th May 2016
Registration Number
5332632 registered on 14th Nov 2017
Filing Basis
1. intent to use
Disclaimer
NO DATA
Logo Mark Trademark Information
Live animals; live mice Scientific and technological services, namely, scientific research, analysis and testing, and research and design in the field of therapeutic pharmaceuticals; scientific laboratory services; laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific informatio Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Scientific and technological services, namely, scientific research, analysis and testing, and research and design in the field of therapeutic pharmaceuticals; scientific laboratory services; laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, therapeutic products
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [031]
Natural Agricultural Products
Live animals; live mice
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; monoclonal antibody therapeutic preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibodies and antibody fragments being diagnostic reagents for medical and veterinary diagnostics; antibodies and antibody fragments for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases for use in the manufacture of therapeutic products
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Chemicals for use in industry and science; chemicals test kits for in vitro testing for laboratory research purposes; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for scientific and laboratory research use; biochemical, namely, monoclonal antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [040]
Treatment & Processing of Materials Services
Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 87052324
Mark Type
No Service Mark
Attorney Docket Number
No 60895-403227
44D Filed
Yes
44D Current
No
44E filed
No
44E Current
Yes
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Design Code(s)
26.01.03 -
Incomplete circles (more than semi-circles)
Legal History
| Status Date | Action Taken |
|---|---|
| 28th May 2024 | CANCELLED SEC. 8 (6-YR) |
| 14th Nov 2022 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| 14th Nov 2017 | REGISTERED-PRINCIPAL REGISTER |
| 29th Aug 2017 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 29th Aug 2017 | PUBLISHED FOR OPPOSITION |
| 09th Aug 2017 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 26th Jul 2017 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 19th Jul 2017 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 19th Jul 2017 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 18th Jul 2017 | ASSIGNED TO LIE |